Overall clinical evaluation of cefpodoxime proxetil against infections in pediatric fields

Ryochi Fujii, Hidenori Meguro, Osamu Arimasu, Hiroaki Shiraishi, Toshiaki Abe, Hajime Yoshioka, Hiroshi Sakata, Kenichi Iseki, Yoji Takahashi, Koichi Murono, Yoshinori Wagatsuma, Akira Watanabe, Masahito Koshinami, Masaru Yokoyama, Shigeru Kimura, Mikio Minamitani, Kei Hachimori, Hiroshi Hayakawa, Yukishige Yanagawa, Haruo IchihashiHiroshi Hirosawa, Yasuko Ishikawa, Shintaro Takahashi, Hiroo Matsuda, Susumu Nakazawa, Hajime Satou, Kenji Niino, Akira Narita, Makoto Hori, Yoshikiyo Toyonaga, Morimasa Sugita, Keisuke Sunakawa, Hironobu Akita, Satoshi Iwata, Yoshitake Sato, Naoichi Iwai, Haruhi Nakamura, Mitsunobu Miyazu, Youichi Taneda, Kuniyoshi Kuno, Hiroshi Kimura, Hidetoshi Takeuchi, Hideki Ishikawa, Fumio Hayakawa, Naoki Yamamoto, Yoshikuni Nakao, Tadafumi Nishimura, Shigeyuki Aoki, Kazuo Tabuki, Yutaka Kobayashi, Tsunekazu Haruta, Shigekazu Kuroki, Takashi Motohiro, Yasutaka Sakata, Tohru Nishiyama, Kouji Ishimoto, Kaoru Tominaga, Fumio Yamashita, Kaoru Ajimine, Koichi Deguchi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Dry syrup and tablet of newly developed Cefpodoxime proxetil (CS-807, CPDX-PR) was investigated in the departments of pediatrics of 17 institutes and their related hospitals. 1. Pharmacokinetics of CPDX-PR in pediatrics were investigated. Peak blood levels of CPDX at dose levels of 3 mg/kg and 6 mg/kg were 2.24±0.21 and 4.68±0.54 μg/ml, respectively, in fasting and 1.65±0.07 and 3.71+0.41 μg/ml, respectively, after meal. Urinary recovery rates in 6 hours were 31.2±2.2% of dose in average. 2. Clinical efficacies of CPDX-PR on various infectious diseases were studied in 748 cases. Clinical efficacy rate in 499 cases with causative bacteria isolated was 94.6%: efficacy rates for individual infections were 96.8% (120/124) for tonsillitis, 96.0% (96/100) for urinary tract infection, 93.5% (58/62) for pneumonia, 92.4% (61/66) for impetigo, 100% (32/32) for scarier fever and 93.2% for pharyngitis or laryngitis. Bacteriological eradication rate for Gram-positive organisms was 91.0% (244/268); and for Gram-negative organisms, 89.7% (210/234). The clinical efficacy rate for cases which were non-responsive to previous antibiotic therapy was 88.1% (74/84). 3. Side effects and clinical laboratory findings were investigated in 779 cases. Two each of vomiting, loose stool and rash, 10 of diarrhea and 1 of diarrhea associated with candidiasis were reported, but no serious side effects were noted. There was no serious laboratory test abnormality except slight elevations of eosinophile, platelet, transaminase or prolongation of prothrombin time, totalling 34 occurrences.

Original languageEnglish
Pages (from-to)1439-1455
Number of pages17
Journalthe japanese journal of antibiotics
Volume42
Issue number7
DOIs
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Overall clinical evaluation of cefpodoxime proxetil against infections in pediatric fields'. Together they form a unique fingerprint.

  • Cite this

    Fujii, R., Meguro, H., Arimasu, O., Shiraishi, H., Abe, T., Yoshioka, H., Sakata, H., Iseki, K., Takahashi, Y., Murono, K., Wagatsuma, Y., Watanabe, A., Koshinami, M., Yokoyama, M., Kimura, S., Minamitani, M., Hachimori, K., Hayakawa, H., Yanagawa, Y., ... Deguchi, K. (1989). Overall clinical evaluation of cefpodoxime proxetil against infections in pediatric fields. the japanese journal of antibiotics, 42(7), 1439-1455. https://doi.org/10.11553/antibiotics1968b.42.1439